Diabetes drug shows benefits for patients with liver disease

image via Medical Xpress - medical research advances and health news

June 4, 2025, 10:30 PM

• •A clinical trial published in The BMJ found that the SGLT-2 inhibitor drug dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients.
• •The trial involved 154 adults diagnosed with MASH, with results showing significant improvement in the dapagliflozin group compared to the placebo group.
• •Researchers acknowledge the study's limitations but suggest the findings are robust, concluding that dapagliflozin may affect key aspects of MASH.
• •Large-scale trials are needed to confirm these effects, with future treatments expected to be tailored to individual patient profiles.

A study published in The BMJ shows that the drug dapagliflozin, commonly used for type 2 diabetes, improves conditions for patients with progressive liver disease. The trial involved 154 adults with metabolic dysfunction-associated steatohepatitis (MASH), revealing that dapagliflozin improved both MASH and liver fibrosis compared to a placebo. The researchers concluded that dapagliflozin may significantly impact MASH by improving both steatohepatitis and fibrosis. While acknowledging study limitations, they suggest that large-scale trials are needed to confirm these promising effects, with future treatments likely tailored to individual patients.

Read original article